Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
about
MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activationCardiovascular safety of anti-diabetic drugsDelay in oral mucosal ulcer healing by aspirin is linked to the disturbances in p38 mitogen-activated protein kinase activationPhytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterationsThe current role of thiazolidinediones in diabetes management.The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cellsEffect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humansInsulin sensitisation in the treatment of Type 2 diabetes.Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptorsPharmacologic treatment of type 2 diabetic dyslipidemia.Idealized PPARγ-Based Therapies: Lessons from Bench and BedsideA phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics.In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.Recent findings concerning thiazolidinediones in the treatment of diabetes.Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With LipodystrophyPPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and OpportunitiesSelective modulation of promoter recruitment and transcriptional activity of PPARgamma.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathwaysPharmacogenetics of the PPAR genes and cardiovascular disease.Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF ratsThe peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.Pleiotropic effects of thiazolidinediones.PPARgamma and its ligands: therapeutic implications in cardiovascular disease.Thiazolidinediones in type 2 diabetes: a cardiology perspective.The possible role of peroxisome proliferator-activated receptor gamma in heart failure.Drug-eluting stent safety: findings from preclinical studies.PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.PPAR agonists as therapeutics for CNS trauma and neurological diseases
P2860
Q21342745-B6726392-A26F-4E42-99A2-50716345315AQ26741082-4FBA4BA1-24B3-4114-B94E-DD89FCB3F804Q28186400-D82F908A-F5D5-49B6-96A5-A68208338C72Q28484781-34E9097B-9B22-4B78-AC8F-559004038929Q30250347-A5CCD2BB-ED71-4D25-9084-25D68AA0A853Q30486738-9E76079F-FDF4-4D8C-A6A6-71E15A0666BEQ33727061-4F9CDFDF-B524-4A46-91ED-FDC07A919185Q33779662-514F108E-E803-4A14-9DA2-E053699E06DEQ34315432-30E83264-0E1A-4DC4-8563-189063C683C0Q34360098-64E103D4-D7B1-4A9F-A9AE-B1D6875F603BQ34395184-40ABE875-4643-4DA3-9D36-460E1FD4D2A4Q34509964-99DFE031-990D-40B5-BDA6-D9E26BC91CD0Q34781949-8E51752F-73A3-4D84-84F8-CD199E2CACD4Q35019725-8DB8EC0C-2C26-4B3B-A43D-75E129E6A6E4Q35073317-CAE39226-B028-4D12-8A52-E6A508BFAE35Q35603688-BC9F99F8-7F3A-4D49-BDAF-4535C5F5F800Q35976827-3F731C14-FB04-4CA7-BA6E-E27BE4F8ED2BQ36056207-8AC4EF04-6158-4A4B-B170-D066AF2AED43Q36094168-4D1C6DDE-549A-4F83-8D13-74F63603B6ECQ36319330-B7ACED40-31A8-421E-BE53-33174C1E7933Q36326205-C6875BF2-A5AD-4F9F-973C-7BBC834A7156Q36363679-344BC7EB-5A05-4B75-9BD8-704BA5DF457BQ36407304-BDC971C4-5375-455A-B252-850AC02B22DDQ36444964-F3029757-9E55-44DC-9AA7-70739D8AF18EQ36787677-D32E68E5-6361-4ECA-9B93-8F3E439C0A5FQ36935534-5C96667A-ADE6-44A3-8EDA-C4A216EBE756Q36959065-6C7C2A2D-D667-48C1-A703-87195B107D53Q36979694-E9CEABE9-61A2-44AA-94E7-06740DD4FE4FQ36992256-24E137DD-5324-4B20-8CD7-348ECA08E338Q37001526-C4B4A64C-10D6-494A-828D-F4347594AAA1Q37012017-66E6032C-9EC4-4B77-A661-42FC667D0497Q37065532-67713E30-1B66-470F-934F-BCC465EA5E70Q37079828-4E88EF14-361D-4E4D-827A-77CF4228E393Q37142044-06D8C978-CD7B-4E2E-AE22-5651C4609938Q37179467-AF61CBE5-E45F-4672-BE98-CF7C18129B6FQ37242253-D8B7FA7A-D28F-4F79-A63C-19015A2CC5ABQ37277818-66B31B6C-D605-41E5-92AE-29EB1F111A6AQ37329149-B21BA1A3-1243-4A69-80D3-052269A49F96Q37362740-C6F1CCBA-6D7A-4A59-B6E0-BBC88D712D1FQ37400355-099E02AB-40ED-43A4-9913-51F6A45291BA
P2860
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Activation of human peroxisome ...... PAR) subtypes by pioglitazone.
@en
type
label
Activation of human peroxisome ...... PAR) subtypes by pioglitazone.
@en
prefLabel
Activation of human peroxisome ...... PAR) subtypes by pioglitazone.
@en
P2093
P356
P1476
Activation of human peroxisome ...... PAR) subtypes by pioglitazone.
@en
P2093
Moriyama S
Sakamoto J
Sugiyama Y
P304
P356
10.1006/BBRC.2000.3868
P577
2000-11-01T00:00:00Z